MSD (Merck Sharp & Dohme)


Research-intensive biopharmaceutical company focused on discovery, development and global delivery of medicines and vaccines across multiple therapeutic areas. Operates global R&D and manufacturing capabilities, runs large clinical trial programs, pursues collaborations and licensing, and maintains enterprise programs for sustainability, supplier engagement and impact investing.

Industries

biopharma
biotechnology
health-care
medical
pharmaceutical

Nr. of Employees

Very Large (1000+)

MSD (Merck Sharp & Dohme)

Kenilworth, New Jersey, United States, North America


Products

Medicines and vaccines across therapeutic areas

Commercial medicines and vaccines developed for oncology, infectious diseases, cardiovascular disease, immunology, neuroscience, ophthalmology and other areas; distributed globally through clinical and commercial channels.

Multivitamin (with

Veterinary multivitamin formulation containing retinyl propionate, tocopheryl acetate, and colecalciferol in a liquid amber form.

Multivitamin (with Starch) Formulation

Multivitamin formulation with starch used as a veterinary product.

Bravecto

1-month chewable tablets containing 560 mg fluralaner for very large dogs.

BRAVECTO 112.5 MG FLURALANER CHEWABLE TABLETS FOR VERY SMALL DOGS

Chewable tablets containing 112.5 mg fluralaner for very small dogs.

Fluralaner / Moxidectin Liquid Formulation

A veterinary liquid formulation containing fluralaner and moxidectin for use as a veterinary antiparasitic product.

View All Products

Services

End-to-end clinical trial services including protocol design, monitoring, patient recruitment, biostatistics and data management.

Enterprise manufacturing operations and partnerships for APIs, large‑ and small‑molecule production, packaging and clinical supply distribution.

Business development and licensing to enable external collaborations, in‑licensing and out‑licensing of assets and technologies.

Programs for supplier inclusion, small business development, environmental sustainability and procurement training/mentoring.

Impact investing into funds and companies to support health system infrastructure, diagnostics, digital solutions and other interventions that strengthen access to care in low‑ and middle‑income settings.

Expertise Areas

  • Clinical trial management
  • Diversity and access planning in clinical research
  • Vaccine and biologics development
  • Oncology research and immunotherapy
  • Show More (8)

Key Technologies

  • Machine learning
  • Artificial intelligence for research and diagnostics
  • Blockchain for supply‑chain integrity
  • Digital health and telehealth platforms
  • Show More (4)

News & Updates

Corporate impact and sustainability report summarizing access, environmental and ethics programs.

Company founded in 1891 and established early research laboratories supporting long-term pharmaceutical research.

Approval of the first recombinant hepatitis B vaccine, marking an early recombinant biologics milestone.

Regulatory approval of an anti–PD-1 immunotherapy for cancer, representing a major advance in oncology development.

Regulatory approval of an Ebola Zaire vaccine to prevent disease caused by Zaire ebolavirus.

Recognitions for impact investing and social impact work, including Fast Company World Changing Ideas honoree (2024), Reuters Social Impact Award finalist (2023) and Fortune Change the World list (2020).


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.